Related references
Note: Only part of the references are listed.A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Aurelie Kamoun et al.
EUROPEAN UROLOGY (2020)
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer
Tania Franceschini et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
Veronica Mollica et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Veronica Mollica et al.
CANCERS (2020)
Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma
Michael Lattanzi et al.
CURRENT ONCOLOGY REPORTS (2019)
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Joya-Rita Hindy et al.
FUTURE ONCOLOGY (2019)
Molecular and histopathology directed therapy for advanced bladder cancer
Constantine Alifrangis et al.
NATURE REVIEWS UROLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Recent developments in the treatment of advanced bladder cancer
James Luke Godwin et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
Tom Powles et al.
EUROPEAN UROLOGY (2017)
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
Pontus Eriksson et al.
ONCOTARGET (2017)
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
Bernhard Kiss et al.
SCIENTIFIC REPORTS (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer
Matteo Santoni et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence
Benjamin A. Mooso et al.
JOURNAL OF UROLOGY (2015)
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Margaret A. Knowles et al.
NATURE REVIEWS CANCER (2015)
Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base
Angela B. Smith et al.
BJU INTERNATIONAL (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
M. D. Galsky et al.
ANNALS OF ONCOLOGY (2012)
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
Christian Bolenz et al.
BJU INTERNATIONAL (2010)
HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder:: Prognostic implications
S Krüger et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
